Fellow degenerates, while everyone is gambling on AI hardware, the market is completely mispricing a $24 billion biotech sitting on an $18 billion cash pile. I am talking about BioNTech (BNTX). Yes, the company that made the COVID 19 vaccine and saved your grandmother.
They just dropped absolute nuke data at the ASCO 2026 medical conference yesterday (May 30, 2026), and the market is about to violently reprice this stock on Monday morning. Here is the ultimate DD on why BNTX is about to print and how I am playing it.
1. The Keytruda Killer is Here
Merck makes $25 billion a year from a lung cancer drug called Keytruda. BioNTech wants that money. They built a bispecific antibody called pumitamig (BNT327) that targets both PD L1 and VEGF A at the same time. Bristol Myers Squibb already paid them a massive $1.5 billion upfront cash check last year just to partner on it.
Yesterday afternoon (Abstract 8513), BioNTech presented the Phase 2 interim data from their ROSETTA Lung 02 trial for patients with first line advanced non small cell lung cancer.
The results? Absolutely filthy.
- The lower dose showed a confirmed objective response rate of 72.7% in squamous lung cancer subtypes.
- For the nonsquamous subtypes, the lower dose hit a 63.6% confirmed objective response rate.
- It worked across all PD L1 expression levels, even when the expression was less than 1%.
- More than 2,000 patients have been treated with pumitamig in clinical trials so far.
2. The Safety Profile Destroyed the Bear Thesis
The bears said targeting VEGF A would cause massive internal bleeding and toxicities. The data just proved them completely wrong.
- The safety profile was highly manageable with a very low discontinuation rate.
- Only 4.7% of patients had severe immune related adverse events.
- Bleeding events occurred in 20.9% of patients, but only a single event was grade 3 (severe).
3. The FDA Fast Track Exploit
Because the lower dose worked so well, they are evaluating it versus pembrolizumab (Keytruda) plus chemotherapy in the ongoing Phase 3 trial. But here is the real kicker: they changed the primary endpoint to Progression Free Survival. They do not have to wait years for Overall Survival data. If they prove the tumor stops growing faster than Keytruda does, they can file for FDA approval much earlier than the street expects.
4. The Deep Oncology Bench
BNTX is not a one trick pony. They have more than 25 Phase 2 and Phase 3 clinical trials running right now. This includes 13 pivotal trials. They have a massive catalyst pipeline for the rest of 2026, including data for gotistobart (their CTLA 4 inhibitor) and filings for their antibody drug conjugates.
My Positions
Given the $18 billion cash runway and the ASCO data confirming the efficacy of pumitamig, the upside is highly asymmetric. UBS just upgraded them to a Buy with a $135 price target.
I am playing the immediate gap up volatility and leaving runners for the institutional upgrades. Here is my current YOLO:
- Position 1: 8 contracts of BNTX JUN 18 2026 95 Call
- Position 2: 5 contracts of BNTX JUL 17 2026 95 Call + 105 Call
- Position 3: 10 contracts of BNTX SEP 18 2026 110 Call
I bought them Tuesday 26th and they are already btw 30% and 45% up.
TLDR: BNTX has enormous cash pile and just proved their flagship cancer drug works flawlessly. Monday is going to be wild.